Medicare Enrolled
Dr. George James, M.D.
Cardiovascular Disease · Fort Worth, TX
Practice pattern: Electrophysiology & Remote— Practice combining electrophysiology and remote services
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. James from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. James? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. James
Dr. George James is a cardiovascular disease in Fort Worth, TX, with 20 years in practice. Based on federal Medicare data, Dr. James performed 4,759 Medicare services across 2,852 unique beneficiaries.
Between the years covered by Open Payments, Dr. James received a total of $9,689 from 37 pharmaceutical and/or device companies across 287 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. James is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 18% volume in TX$ $9,689 industry payments
Medicare Practice Summary
Medicare Utilization ↗4,759
Medicare services
Top 18% in TX for cardiovascular disease
2,852
Unique beneficiaries
$72
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~238 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) | 645 | $93 | $231 |
| Electrocardiogram (EKG), 12-lead | 575 | $10 | $42 |
| Remote pacemaker/defibrillator monitoring, 90 days | 427 | $16 | $66 |
| Remote pacemaker monitoring, 90 days | 421 | $20 | $74 |
| Office visit, established patient (20-29 min) | 396 | $61 | $156 |
| Regadenoson injection (Lexiscan) for heart stress test | 244 | $44 | $120 |
| Hospital follow-up visit, moderate complexity | 175 | $61 | $155 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 172 | $29 | $75 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 160 | $20 | $59 |
| Hospital follow-up visit, high complexity | 141 | $93 | $223 |
| Echocardiogram, transthoracic | 111 | $144 | $469 |
| Hospital follow-up visit, low complexity | 101 | $37 | $85 |
| New patient office visit, complex (60-74 min) | 86 | $151 | $442 |
| Prothrombin time test (blood clotting) | 84 | $4 | $13 |
| Initial hospital admission, high complexity | 81 | $135 | $434 |
| Sleep study including heart rate, breathing, and sleep time | 79 | $83 | $903 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 68 | $50 | $196 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 63 | $9 | $150 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 51 | $2 | $30 |
| Office visit, established patient, complex (40-54 min) | 46 | $125 | $310 |
| Programming of dual lead pacemaker system | 44 | $62 | $132 |
| Ultrasound of heart blood flow, valves and chambers | 42 | $14 | $42 |
| Ultrasound of both sides of head and neck blood flow | 42 | $145 | $543 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 42 | $676 | $971 |
| Ultrasound of heart with probe in esophagus, with report | 41 | $75 | $237 |
| Ultrasound of heart, follow-up | 40 | $19 | $102 |
| EKG interpretation and report | 36 | $6 | $121 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 33 | $1,057 | $2,490 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 33 | $149 | $224 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 31 | $315 | $1,111 |
| Cardiac catheterization | 30 | $216 | $600 |
| Office visit, established patient (10-19 min) | 27 | $38 | $94 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 23 | $20 | $75 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 22 | $663 | $900 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 19 | $376 | $1,174 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 19 | $234 | $636 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 18 | $9 | $32 |
| External shock to heart to regulate heart beat | 17 | $79 | $535 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $56 | $95 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 16 | $15 | $42 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 15 | $6 | $14 |
| New patient office visit (45-59 min) | 15 | $113 | $355 |
| Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | 11 | $198 | $950 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
24.7% high complexity
10.5% medium
64.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,689
Total received (2018-2024)
Avg $1,384/year across 7 years
Top 33% in TX for cardiovascular disease
37
Companies
287
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,689 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,643
2023$1,027
2022$1,615
2021$1,014
2020$677
2019$875
2018$2,838
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
BIOTRONIK INC.
$3,325
Medtronic, Inc.
$1,200
Actelion Pharmaceuticals US, Inc.
$789
Abbott Laboratories
$575
Novartis Pharmaceuticals Corporation
$573
Janssen Pharmaceuticals, Inc
$399
E.R. Squibb & Sons, L.L.C.
$333
AstraZeneca Pharmaceuticals LP
$289
Amgen Inc.
$228
PFIZER INC.
$204
Boehringer Ingelheim Pharmaceuticals, Inc.
$202
SANOFI-AVENTIS U.S. LLC
$182
HeartFlow, Inc.
$166
ZOLL Respicardia, Inc.
$139
BOSTON SCIENTIFIC CORPORATION
$125
Edwards Lifesciences Corporation
$110
Merck Sharp & Dohme LLC
$109
United Therapeutics Corporation
$89
Itamar Medical Inc
$75
Invuity, Inc.
$63
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$56
Gilead Sciences, Inc.
$51
Teleflex LLC
$49
Merck Sharp & Dohme Corporation
$41
Medtronic Vascular, Inc.
$35
SCPHARMACEUTICALS INC.
$33
Kiniksa Pharmaceuticals, Ltd.
$32
ARBOR PHARMACEUTICALS, INC.
$31
Terumo Medical Corporation
$30
HEARTFLOW, INC.
$26
Avinger Inc.
$24
Lexicon Pharmaceuticals, Inc.
$24
Regeneron Healthcare Solutions, Inc.
$23
Novo Nordisk Inc
$18
Boston Scientific Corporation
$18
Amarin Pharma Inc.
$14
Kowa Pharmaceuticals America, Inc.
$12
Top 3 companies account for 54.8% of total payments
Associated products mentioned in payments ›
AMVIA EDGE · ANGIO-SEAL · Acticor · Acticor 7 VR-T DX · Amplia MRI · BIOMONITOR · BRILINTA · CAMZYOS · CARDIOMEMS · CardioMEMS HF System · Catheter - GuideLiner · Confirm Rx · Connectivity and Remote care · Corlanor · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · ENTRESTO · Edarbi · Edarbyclor · Edora · Edora 8 DR-T · FARXIGA · FFRct · FUROSCIX · HeartMate 3 Left Ventricular Dev · Inpefa · JARDIANCE · LEQVIO · LOKELMA · LifeVest · Livalo · MICRA · MITRACLIP · MULTAQ · OPSUMIT · ORENITRAM · Ozempic · PANTHERIS · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Photonblade · QUADRA ASSURA · Quadra Assura CRT Defibrillator · ROTABLATOR · Repatha · Reveal LINQ · Rist-7F · SAPIEN 3 Ultra RESILIA · SPECTRA WAVEWRITER · Solia · THORATEC HEARTMATE 3 LVAS IMPLANT KIT · TYVASO · UPTRAVI · VERQUVO · VYNDAQEL · Vascepa · WATCHMAN · WatchPATONE · XARELTO · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $204 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
92
Per 100K population
4.3
County median income
$81,905
Nearest hospital
TEXAS HEALTH HARRIS METHODIST HOSPITAL AZLE
6.9 mi
6.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. James is a electrophysiology & remote specialist, with above-average Medicare volume (top 18% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. James experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. James performed 645 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. James receive payments from pharmaceutical companies?
Yes. Dr. James received a total of $9,689 from 37 companies across 287 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. James's costs compare to other cardiovascular diseases in Fort Worth?
Dr. James's average Medicare payment per service is $72. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. James) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Fort Worth
Browse cardiovascular diseases in Fort Worth ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
BIOTRONIK INC. Payments to Doctors
See all physicians who received payments from BIOTRONIK INC..
By company
Medtronic, Inc. Payments to Doctors
See all physicians who received payments from Medtronic, Inc..
By company
Actelion Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from Actelion Pharmaceuticals US, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology